Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 2Phase 1 2Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 3NET 2Endocrine 2Gastrointestinal 1

Conditions

Neuroendocrine Tumors 1Advanced Gastroenteropancreatic Neuroendocrine Tumor 1

Interventions

Everolimus 7lutetium Lu 177 dotatate 6lanreotide 5Octreotide 5177Lu-octreotide, DOTA(0)-Tyr(3)- 4amino-acid, glucose, and electrolyte solution 3Capecitabine 3surufatinib 2pasireotide 2fluorodopa F 18 2Temozolomide 2Lutetium-177 2Lutetium 2Introns 2Ga(III)-DOTATOC 2telotristat ethyl 1pembrolizumab 1copper dotatate CU-64 1cabozantinib 1X-Rays 1Watchful Waiting 1Sunitinib 1Specimen Handling 1Somatostatin 1Serotonin 1Salts 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Phantoms, Imaging 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Lutetium-177 × NET × Clear all
NCT05884255 2026-05-19

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
220 enrolled
EndocrineGastrointestinalNET

Advanced Gastroenteropancreatic Neuroendocrine Tumor

NCT06878664 2025-09-02

RIALTO

Grupo Espanol de Tumores Neuroendocrinos

Phase 3 Recruiting
166 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡